ASO Visual Abstract: Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score—A Multicenter Study
本文未提供摘要,请点击“查看全文”查看完整内容。